Loading…
Intas Pharmaceuticals Limited's drug manufacturing facility in India was found to have committed significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their products adulterated. The company's quality control unit failed to exercise adequate oversight, and investigators discovered that visual inspectors systematically manipulated particle defect counts and other quality data on inspection records since 2021 to artificially keep batches within acceptable limits and avoid deviations. Multiple operators engaged in this data manipulation to circumvent proper deviation investigations and maintain compliance appearances. The violations demonstrated a breakdown in quality assurance and production department controls that failed to ensure the reliability of drug product quality data.